Quick Facts
FONT-SIZE Plus   Neg
Share SHARE
mail  E-MAIL

AngioDynamics Receives FDA Clearance For BioFlo PICCs With Endexo Technology

RELATED NEWS
Trade ANGO now with 
8/29/2012 6:40 AM ET

AngioDynamics Inc. (ANGO: Quote) announced the U.S. Food and Drug Administration has granted 510(k) clearance for its BioFlo peripherally inserted central catheters or PICCs with Endexo technology designed to reduce the accumulation of catheter-related thrombus on, and in, the catheter.

It is expected to launch in the second quarter of fiscal year 2013. These products are currently CE marked for Europe and are approved in Canada and other international markets.

"We expect to launch BioFlo technology with PASV PICCs in the U.S. within the next 30 days," said Chuck Greiner, Vice President of the Global Vascular Access Franchise.

Click here to receive FREE breaking news email alerts for AngioDynamics Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
The Bank of Japan on Wednesday decided to keep its ultra-loose monetary policy unchanged, as expected, suggesting that the bank is moving cautiously amid concerns over the recent turmoil in the bond market. The policy board said the bank will conduct money market operations so that the monetary base will increase at an annual pace of about JPY 60-70 trillion. Confidence among Australian consumers declined sharply in May to its lowest level since August 2012, driven largely by negative responses to the Federal Budget, a survey by Westpac and Melbourne Institute showed Wednesday. The index of consumer sentiment fell 7 percent in May to 97.6 from 104.9 in April. This is the lowest reading since August 2012. Data-storage products maker NetApp Inc. said Tuesday after the markets closed that its fourth quarter profit fell 4% from last year, hurt mainly by higher operating expenses even as revenue grew slightly. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations, but its quarterly revenue fell short of analysts' forecast.
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.